Navigation Links
Quark Pharmaceuticals and Major Pharmaceutical Company Enter into Licensing Option Agreement for the p53 Suppressor Drug QPI-1002, the First siRNA Administered Systemically in Human
Date:8/18/2010

ent populations and an independent Data Safety Monitoring Board recommended continuation of QPI-1002 clinical development in both diseases. QPI-1002 was granted Orphan designation by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the prophylaxis of delayed graft function in kidney transplant patients.

About Quark Pharmaceuticals, Inc.Quark Pharmaceuticals, Inc., a world leader in novel RNAi discovery and development, has the largest clinical-stage siRNA pipeline in the industry. The Company's fully integrated drug development platform spans therapeutic target identification to drug development.  Quark's approach to delivery allows targeting of tissues and organs including the eye, kidney, ear, lung, spinal cord and brain.

In addition to QPI-1002, Quark's pipeline includes PF-655, currently in two Phase II clinical trials for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME). The siRNA therapeutic candidate PF-655 is licensed to Pfizer, who is conducting both trials in collaboration with Quark. PF-655 targets Quark's proprietary gene, RTP801, discovered using its BiFAR™ target discovery platform that identifies clinically relevant critical genes and proteins that reverse the disease phenotype when inhibited. The Company owns a family of patents covering the RTP801 gene, its RNA and protein product sequences, specific antibodies, and gene inhibition across different pathologies. For the structure of these products, Quark has obtained licenses from Silence Therapeutics and from Alnylam Pharmaceuticals.

Quark is currently conducting clinical trials of QPI-1007, its proprietary synthetic siRNA drug candidate for ocular neuroprotection. QPI-1007 utilizes a proprietary structure developed in collaboration with BioSpring GmbH that provides Quark with freedom to operate in the siRNA intellectual property arena and chemical modifications that are designed to pr
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
3. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
6. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
7. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
8. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
9. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
10. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
11. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... DIEGO , 29 septembre 2014 ... (TSE : 4568) et Ambit Biosciences (NASDAQ : AMBI), ont ... fusion définitif en vertu duquel Daiichi Sankyo fera ... circulation d,Ambit Biosciences à 15 dollars par action ... d,achat qui sera suivie d,une fusion avec une ...
(Date:9/29/2014)... , Sept. 29, 2014 Pharmacists ... trials are conducted according to good clinical trials ... HOPA Investigational Drug Service Best Practice Standards, the ... practice standards and guidance for pharmacists and institutions ... Service Best Practice Standards emphasizes the critical role ...
(Date:9/29/2014)... Calif. , Sept. 29, 2014  Bob Pack, ... driver, today called on the California Medical Association to ... Proposition 46 that the San Jose Mercury News called ... "practically everything it wants voters to believe about the ... ad attacks the Prop 46 requirement that doctors check ...
Breaking Medicine Technology:Daiichi Sankyo va acquérir Ambit Biosciences 2Daiichi Sankyo va acquérir Ambit Biosciences 3Daiichi Sankyo va acquérir Ambit Biosciences 4Daiichi Sankyo va acquérir Ambit Biosciences 5Daiichi Sankyo va acquérir Ambit Biosciences 6Daiichi Sankyo va acquérir Ambit Biosciences 7Daiichi Sankyo va acquérir Ambit Biosciences 8Daiichi Sankyo va acquérir Ambit Biosciences 9HOPA Introduces First Investigational Drug Service Best Practice Standards For Institutions And Infusion Clinics 2HOPA Introduces First Investigational Drug Service Best Practice Standards For Institutions And Infusion Clinics 3Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 2Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 3Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 4Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 5
(Date:9/30/2014)... Steven Reinberg HealthDay Reporter ... fish oil supplements won,t prevent the return of a common ... report. In fact, 64.1 percent of those taking fish ... atrial fibrillation over the course of 16 months, compared to ... supplements also did not reduce the twin ills of inflammation ...
(Date:9/30/2014)... Francisco, California (PRWEB) September 30, 2014 ... expected to reach USD 38.75 billion by 2020 at ... according to a new study by Grand View Research, ... disorders due to lifestyle habits such as excessive alcohol ... in organ failure rates is expected to serve this ...
(Date:9/30/2014)... California (PRWEB) September 30, 2014 ... to reach USD 8,020.1 million by 2020, according ... Inc. Growing demand for personalized medicine and theranostics, ... technologies are expected to be key factors driving ... the growing global base of geriatric population and ...
(Date:9/30/2014)... AutoTex PINK proudly offers ... ribbon in support of breast cancer awareness and research ... and non-profits to “go pink” -- supporting walks, runs ... is a woman-owned company that is among the nation’s ... to partnering with their customers to raise breast cancer ...
(Date:9/30/2014)... MN (PRWEB) September 30, 2014 ... leader in business technology and services was recognized ... First Call Effectiveness (FCE) in 2013. This prestigious ... properly the first time and for an extended ... For more than 20 years BEI Services has ...
Breaking Medicine News(10 mins):Health News:Fish Oil Supplements Have Little Effect on Irregular Heartbeat: Study 2Health News:Fish Oil Supplements Have Little Effect on Irregular Heartbeat: Study 3Health News:Global Artificial Organ & Bionics Market Is Expecting Growth At CAGR Of 40.0% In Brain Bionics Segment From 2014 To 2020: Grand View Research, Inc. 2Health News:Global Artificial Organ & Bionics Market Is Expecting Growth At CAGR Of 40.0% In Brain Bionics Segment From 2014 To 2020: Grand View Research, Inc. 3Health News:Global Artificial Organ & Bionics Market Is Expecting Growth At CAGR Of 40.0% In Brain Bionics Segment From 2014 To 2020: Grand View Research, Inc. 4Health News:Global Artificial Organ & Bionics Market Is Expecting Growth At CAGR Of 40.0% In Brain Bionics Segment From 2014 To 2020: Grand View Research, Inc. 5Health News:Global Artificial Organ & Bionics Market Is Expecting Growth At CAGR Of 40.0% In Brain Bionics Segment From 2014 To 2020: Grand View Research, Inc. 6Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 2Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 3Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 4Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 5Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 6Health News:Change Your Blades … Change A Life! AutoTex PINK Wiper Blades Are Helping Wipe Out Breast Cancer 2Health News:Change Your Blades … Change A Life! AutoTex PINK Wiper Blades Are Helping Wipe Out Breast Cancer 3Health News:Loffler Companies Rated Number One Among U.S. Dealers in Service “First Call Effectiveness” 2Health News:Loffler Companies Rated Number One Among U.S. Dealers in Service “First Call Effectiveness” 3
... ease a downsized employee,s healthcare and financial distress. , ... Nashville, Tenn. ... December 2007 - and more than 1.7 million in the last three ... loss of healthcare coverage and the unpredictable cost of medical care can ...
... Investors need a plan to deal with market stress, ... plan to deal with the stress of the market, ... at a recent gathering of the Greenwich Roundtable, a ... capital to alternative investments.Kiev, president of Kiev Consulting, coaches ...
... - With Photo , ... went,head-to-head to win a GBP2,000 investment from TV Dragon Duncan Bannatyne. ... toughest,challenge yet when they presented their big ideas on how they ... Shannon Stokes, 9, from Neith, South Wales, won with her proposal ...
... recruitment and career opportunities to address ongoing needs., , ... ... and as unemployment climbs, many healthcare fields are still stable or ... February, with a gain of 27,000. Job growth occurred in ambulatory ...
... Critical to Improving Quality of U.S. HealthcarePLANO, Texas, March ... ), the U.S. market leader for providing healthcare IT ... a second comprehensive webinar about the impact that the ... have on the U.S. Healthcare industry. The webinar ...
... Mental Illness (NAMI) Michigan released today the findings of its ... our state. The State of Michigan ... rating . Fourteen states improved their grades from 2006 and ... Michigan,s mental health care system has deteriorated even further this ...
Cached Medicine News:Health News:change:healthcare Helps Displaced Employees Immobilized by High Cost of Healthcare 2Health News:change:healthcare Helps Displaced Employees Immobilized by High Cost of Healthcare 3Health News:Psychiatrist and Trading Coach Dr. Ari Kiev Addresses Greenwich Roundtable 2Health News:"I'm In" - Duncan Bannatyne Judges "Switch Ash for Cash" Schools Competition 2Health News:"I'm In" - Duncan Bannatyne Judges "Switch Ash for Cash" Schools Competition 3Health News:"I'm In" - Duncan Bannatyne Judges "Switch Ash for Cash" Schools Competition 4Health News:Healthcare Industry Continues to Post Gains in a Down Economy 2Health News:Perot Systems Launches Webinar Series and Website Resources on Healthcare Stimulus Plan Provisions 2Health News:Perot Systems Launches Webinar Series and Website Resources on Healthcare Stimulus Plan Provisions 3Health News:Michigan's Mental Health Care System Gets a D Grade in Latest Study 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: